Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar Guidances: Broader Populations Permitted; More Immunogenicity Requested

Executive Summary

New draft Q&A and three final guidances from FDA offer pros and cons for sponsors of biosimilar applications.

You may also be interested in...



When Drugs Become Biologics: US FDA Guidances Explain 'Transition Provisions'

With two new guidance documents, agency is trying to bring order to the potentially chaotic regulatory process that insulins and other currently approved protein products will face in March 2020; FDA also issues two more Q&A guidance documents on scientific and regulatory considerations for biosimilars.

Extrapolated Biosimilar Indications Won't Get More Post-Marketing Requirements

Biosimilars will have same pharmacovigilance expectations as innovator biologics despite lack of clinical data for some extrapolated indications.

Biosimilar Workload At FDA: Policy Development Far Exceeds Application Review

Even as applications themselves remain low burden, intense policy efforts put pressure on user fees.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS056869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel